Vivek C Kumar

US Patent:

20220265643, Aug 25, 2022

Filed:

May 6, 2022

Appl. No.:

17/738301

Inventors:

- Bethesda MD, US
Vivek KUMAR - Baltimore MD, US
Anver Basha SHAIK - Baltimore MD, US

International Classification:

A61K 31/496
A61P 25/36
A61K 31/485

Abstract:

Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the development of opioid dependence, by preventing the need for dose escalation while either maintaining the opioid analgesic effect or providing analgesia with a lower dose of the opioid. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of opioid use disorders.

US Patent:

20220185798, Jun 16, 2022

Filed:

Mar 3, 2022

Appl. No.:

17/685709

Inventors:

- Rockville MD, US
Vivek KUMAR - Baltimore MD, US
Anver Basha SHAIK - Baltimore MD, US

International Classification:

C07D 403/12
A61P 25/36
C07D 405/12

Abstract:

Disclosed herein novel dopamine D3 receptor selective antagonists/partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic tools. Also disclosed are methods of making the compounds.

US Patent:

20210346373, Nov 11, 2021

Filed:

Sep 9, 2019

Appl. No.:

17/265150

Inventors:

- Bethesda MD, US
Vivek KUMAR - Baltimore MD, US
Anver Basha SHAIK - Baltimore MD, US

International Classification:

A61K 31/496
A61K 31/485
A61P 25/36

Abstract:

Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the development of opioid dependence, by preventing the need for dose escalation while either maintaining the opioid analgesic effect or providing analgesia with a lower dose of the opioid. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of opioid use disorders.

US Patent:

20210220493, Jul 22, 2021

Filed:

Feb 6, 2019

Appl. No.:

16/967488

Inventors:

- Baltimore MD, US
- Durham NC, US
Vivek Kumar - Rensselaer NY, US
Sangeeta Ray - Ellicott City MD, US
Michael Zalutsky - Chapel Hill NC, US
Ganesan Vaidyanathan - Chapel Hill NC, US

International Classification:

A61K 51/04
A61P 35/00

Abstract:

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

US Patent:

20200291000, Sep 17, 2020

Filed:

Sep 21, 2017

Appl. No.:

16/084093

Inventors:

- Bethesda MD, US
Vivek KUMAR - Baltimore MD, US
Anver Basha SHAIK - Baltimore MD, US

International Classification:

C07D 403/12
C07D 405/12
A61P 25/36

Abstract:

Disclosed herein novel dopamine D3 receptor selective antagonists/partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic tools. Also disclosed are methods of making the compounds.